| The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation J Steffel, P Verhamme, TS Potpara, P Albaladejo, M Antz, L Desteghe, ... European heart journal 39 (16), 1330-1393, 2018 | 3142 | 2018 |
| Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation H Heidbuchel, P Verhamme, M Alings, M Antz, HC Diener, W Hacke, ... Ep Europace 17 (10), 1467-1507, 2015 | 1466 | 2015 |
| Statins and postoperative risk of atrial fibrillation following coronary artery bypass grafting F Marín, DA Pascual, V Roldán, JM Arribas, M Ahumada, PL Tornel, ... The American journal of cardiology 97 (1), 55-60, 2006 | 326 | 2006 |
| Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a “real-world” population with atrial fibrillation receiving anticoagulant therapy V Roldán, F Marín, H Fernández, S Manzano-Fernandez, P Gallego, ... Chest 143 (1), 179-184, 2013 | 280 | 2013 |
| The HAS-BLED Score Has Better Prediction Accuracy for Major Bleeding Than CHADS2 or CHA2DS2-VASc Scores in Anticoagulated Patients With Atrial … V Roldán, F Marín, S Manzano-Fernández, P Gallego, JA Vílchez, ... Journal of the American College of Cardiology 62 (23), 2199-2204, 2013 | 245 | 2013 |
| Antithrombotic management in patients undergoing electrophysiological procedures: a European Heart Rhythm Association (EHRA) position document endorsed by the ESC working group … C Sticherling, F Marin, D Birnie, G Boriani, H Calkins, GA Dan, M Gulizia, ... Ep Europace 17 (8), 1197-1214, 2015 | 243 | 2015 |
| Soluble E-selectin in cardiovascular disease and its risk factors V Roldán, F Marín, GYH Lip, AD Blann Thrombosis and haemostasis 90 (12), 1007-1020, 2003 | 227 | 2003 |
| Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation P Gallego, V Roldan, F Marín, M Romera, M Valdés, V Vicente, GYH Lip Thrombosis and haemostasis 110 (12), 1189-1198, 2013 | 219 | 2013 |
| Interleukin-6, endothelial activation and thrombogenesis in chronic atrial fibrillation V Roldán, F Marín, AD Blann, A García, P Marco, F Sogorb, GYH Lip European heart journal 24 (14), 1373-1380, 2003 | 193 | 2003 |
| Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation P Gallego, V Roldán, JM Torregrosa, J Gálvez, M Valdés, V Vicente, ... Circulation: Arrhythmia and Electrophysiology 5 (2), 312-318, 2012 | 186 | 2012 |
| Perioperative and Periprocedural Management of Antithrombotic Therapy: Consensus Document of SEC, Sedar, Seacv, Sectcv, Aec, Secpre, Sepd, Sego, Sehh, Seth, Semergen, Semfyc … D Vivas, I Roldan, R Ferrandis, F Marin, V Roldan, A Tello-Montoliu, ... Revista Española de Cardiología (English Edition) 71 (7), 553-564, 2018 | 184* | 2018 |
| SAMe-TT2R2 score, time in therapeutic range, and outcomes in anticoagulated patients with atrial fibrillation P Gallego, V Roldán, F Marin, J Gálvez, M Valdés, V Vicente, GYH Lip The American journal of medicine 127 (11), 1083-1088, 2014 | 168 | 2014 |
| Plasma von Willebrand factor levels are an independent risk factor for adverse events including mortality and major bleeding in anticoagulated atrial fibrillation patients V Roldán, F Marín, B Muiña, JM Torregrosa, D Hernández-Romero, ... Journal of the American College of Cardiology 57 (25), 2496-2504, 2011 | 168 | 2011 |
| A multimarker risk stratification approach to non‐ST elevation acute coronary syndrome: implications of troponin T, CRP, NT pro‐BNP and fibrin D‐dimer levels A Tello‐Montoliu, F Marin, V Roldan, L Mainar, MT López, F Sogorb, ... Journal of internal medicine 262 (6), 651-658, 2007 | 153 | 2007 |
| Renal impairment in a “real-life” cohort of anticoagulated patients with atrial fibrillation (implications for thromboembolism and bleeding) V Roldán, F Marín, H Fernández, S Manzano-Fernández, P Gallego, ... The American journal of cardiology 111 (8), 1159-1164, 2013 | 144 | 2013 |
| High sensitivity cardiac troponin T and interleukin‐6 predict adverse cardiovascular events and mortality in anticoagulated patients with atrial fibrillation V Roldan, F Marin, J Diaz, P Gallego, E Jover, M Romera, ... Journal of Thrombosis and Haemostasis 10 (8), 1500-1507, 2012 | 141 | 2012 |
| Antithrombin Cambridge II (A384S): an underestimated genetic risk factor for venous thrombosis J Corral, D Hernandez-Espinosa, JM Soria, R Gonzalez-Conejero, ... Blood 109 (10), 4258-4263, 2007 | 139 | 2007 |
| Pharmacogenetics in cardiovascular antithrombotic therapy F Marín, R González-Conejero, P Capranzano, TA Bass, V Roldán, ... Journal of the American College of Cardiology 54 (12), 1041-1057, 2009 | 134 | 2009 |
| Plasma von Willebrand factor, soluble thrombomodulin, and fibrin D-dimer concentrations in acute onset non-rheumatic atrial fibrillation F Marin, V Roldan, VE Climent, A Ibanez, A Garcia, P Marco, F Sogorb, ... Heart 90 (10), 1162-1166, 2004 | 134 | 2004 |
| Premature myocardial infarction: clinical profile and angiographic findings J Pineda, F Marín, V Roldán, J Valencia, P Marco, F Sogorb International journal of cardiology 126 (1), 127-129, 2008 | 127 | 2008 |
Francisco Marin (ORCID: 0000-0001-7...Profesor CardiologiaVerified email at um.es
